10x Genomics (TXG) said late Monday a US court issued a permanent injunction against the sale of GeoMx products by Bruker (BRKR).
The US District Court for the District of Delaware will enter the injunction in January, which will prohibit Bruker from making, using, selling, or offering to sell the GeoMx Digital Spatial Profiler and associated instruments, reagents, and services for RNA and protein detection in the US.
These products were acquired from NanoString Technologies, according to 10x Genomics.
To ensure the continuity of the ongoing research, 10x said it requested an exemption for GeoMx users who installed an instrument before the trial in November 2023.
Additionally, 10x said that the court upheld the November 2023 jury verdict, which awarded the company $31 million in damages after finding that NanoString's GeoMx Digital Spatial Profiler products infringed patents licensed to 10x.
Neither Bruker nor NanoString immediately responded to MT Newswires' request for comment.
Shares of 10x Genomics were up nearly 2% in after-hours trading. Bruker shares were unchanged.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。